

Financial news for OMER dated on 2020-05-14: Omeros To Present Narsoplimab Pivotal Trial Data At European Hematology Association Annual Congress Jun. 11-14

Financial news for OMER dated on 2020-05-11: Omeros Q1 EPS \$(0.530) Misses \$(0.340) Estimate, Sales \$23.537M Miss \$30.270M Estimate

Financial news for OMER dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for OMER dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for OMER dated on 2020-03-04: 85 Biggest Movers From Yesterday

Financial news for OMER dated on 2020-03-03: Mid-Afternoon Market Update: Dow Tumbles 800 Points; Superconductor Technologies Shares Spike Higher

Financial news for OMER dated on 2020-03-03: Mid-Day Market Update: Dow Falls Over 200 Points; Fed Issues Emergency Interest Rate Cut

Financial news for OMER dated on 2020-03-03: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OMER dated on 2020-03-03: Omeros shares are trading higher after the company reported Narsoplimab HSCT-TMA results surpassed the FDA-agreed efficacy threshold.

Financial news for OMER dated on 2020-03-03: Mid-Morning Market Update: Markets Open Higher; Target Posts Mixed Q4 results

Financial news for OMER dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for OMER dated on 2020-03-03: 40 Stocks Moving in Tuesday's Pre-Market Session

Financial news for OMER dated on 2020-03-02: 15 Stocks Moving In Monday's After-Hours Session

Financial news for OMER dated on 2020-03-02: Omeros shares are trading higher after the company reported Narsoplimab HSCT-TMA results surpassed the FDA-agreed efficacy threshold.

Financial news for OMER dated on 2020-03-02: Omeros Q4 EPS \$(0.58) Misses \$(0.5) Estimate, Sales \$33.417M Beat \$31.57M Estimate

Financial news for OMER dated on 2020-03-02: Omeros Offers Updated Results From Narsoplimab HSCT-TMA Trial: 'Results Surpass FDA-Agreed Efficacy Threshold'

Financial news for OMER dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for OMER dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for OMER dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for OMER dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for OMER dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for OMER dated on 2020-02-03: Stocks That Hit 52-Week Lows On Monday

Financial news for OMER dated on 2020-01-31: Stocks That Hit 52-Week Lows On Friday

Financial news for OMER dated on 2019-12-18: myTomorrows And Omeros Corporation Collaborate To Provide An Expanded Access Program For Narsoplimab

Financial news for OMER dated on 2019-12-16: Omeros Highlights Presentation Of GPR174 Immuno-Oncology Data At ESMO Immuno-Oncology Congress Showing Inhibition Of Both Checkpoint And Tumor-Promoting Factors

Financial news for OMER dated on 2019-12-06: 75 Biggest Movers From Yesterday

Financial news for OMER dated on 2019-12-05: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for OMER dated on 2019-12-05: Omeros shares are trading lower after the company reported a proposed public offering of common stock priced in the \$13.10-\$13.40 per share range.

Financial news for OMER dated on 2019-12-05: 17 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for OMER dated on 2019-12-05: 40 Stocks Moving in Thursday's Pre-Market Session

Financial news for OMER dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for OMER dated on 2019-12-04: 7 Stocks Moving In Wednesday's After-Hours Session

Financial news for OMER dated on 2019-12-04: Omeros shares are trading lower after the company reported a proposed public offering of common stock priced in the \$13.10-\$13.40 per share range.

Financial news for OMER dated on 2019-12-04: Hearing Omeros Shares Priced In \$13.10-\$13.40/Share Range For Offering

Financial news for OMER dated on 2019-12-04: Omeros Reports Common Stock Offering, No Size Disclosed

Financial news for OMER dated on 2019-12-04: Omeros Aces Late-Stage Trial Of Transplant Drug Narsoplimab

Financial news for OMER dated on 2019-12-04: Omeros Announces Results Of Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab

Financial news for OMER dated on 2019-12-02: H.C. Wainwright Reiterates Buy on Omeros, Lowers Price Target to \$34

Financial news for OMER dated on 2019-11-19: Omeros Presents New GPR174 Immuno-Oncology Data At American Association For Cancer Research Conference In Boston

Financial news for OMER dated on 2019-11-12: Omeros Q3 EPS \$(0.33) Beats \$(0.41) Estimate, Sales \$29.856M Beat \$27.24M Estimate

Financial news for OMER dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for OMER dated on 2019-11-05: 46 Biggest Movers From Yesterday

Financial news for OMER dated on 2019-11-04: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for OMER dated on 2019-11-04: 24 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for OMER dated on 2019-11-04: 21 Stocks Moving In Monday's Pre-Market Session

Financial news for OMER dated on 2019-10-29: Omeros Reports Narsoplimab Receives Positive Opinion From EMA

Financial news for OMER dated on 2019-10-28: Omeros Corporation Initiates BLA Submission For Narsoplimab For The Treatment Of HSCT-TMA

Financial news for OMER dated on 2019-09-16: Omeros Reports Results From Phase 1 Study Of OMS527 In Development For Addiction

Financial news for OMER dated on 2019-09-10: Omeros Highlights Ability Of GPR174 Inhibitors In Anti-Tumor Activities

Financial news for OMER dated on 2019-08-19: 27 Stocks Moving in Monday's Pre-Market Session

Financial news for OMER dated on 2019-08-12: 90 Biggest Movers From Friday

Financial news for OMER dated on 2019-08-09: 75 Stocks Moving In Friday's Mid-Day Session

Financial news for OMER dated on 2019-08-09: 52 Stocks Moving In Friday's Pre-Market Session

Financial news for OMER dated on 2019-08-08: 50 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for OMER dated on 2019-08-08: Omeros shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for OMER dated on 2019-08-08: Omeros Q2 EPS \$(0.29) Beats \$(0.46) Estimate, Sales \$26.753M Beat \$24.52M Estimate

Financial news for OMER dated on 2019-07-31: Omeros Reports Long-Term Manufacturing Deal With Lonza For Commercial Supply For Narsoplimab, No Terms Disclosed

Financial news for OMER dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for OMER dated on 2019-07-11: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for OMER dated on 2019-07-11: Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment

Financial news for OMER dated on 2019-07-11: Omeros shares are trading higher after the company announced an agreement with the FDA on the primary endpoint for its trial of Narsoplimab BLA in stem cell transplant-associated TMA.

Financial news for OMER dated on 2019-07-11: Omeros Reports FDA Deal On Primary Endpoint For Narsoplimab Biologics License Application In Stem Cell Transplant-Associated TMA

Financial news for OMER dated on 2019-05-10: CORRECTION: Omeros Shares Trading Higher; Recent Headline Which Was Published Incorrectly Suggested Stock Was Lower; However Shares Had Opened Lower This Morning

Financial news for OMER dated on 2019-05-09: Omeros shares are trading lower after the company reported worse-than-expected Q1 EPS results.

Financial news for OMER dated on 2019-05-09: Omeros Q1 EPS \$(0.5) Misses \$(0.27) Estimate

Financial news for OMER dated on 2019-05-06: Cantor Fitzgerald Initiates Coverage On Omeros Corporation - Common Stock with Overweight Rating, Announces \$26 Price Target

Financial news for OMER dated on 2019-03-19: Omeros Corporation Announces Upcoming Educational Event At Annual Meeting Of The European Society Of Blood And Marrow Transplantation

Financial news for OMER dated on 2019-03-01: Omeros shares are trading higher after the company beat Q4 EPS and sales estimates.

Financial news for OMER dated on 2019-03-01: Omeros Q4 EPS \$(0.48) Beats \$(0.67) Estimate, Sales \$22M Beat \$16.08M Estimate

Financial news for OMER dated on 2019-03-01: Earnings Scheduled For March 1, 2019

Financial news for OMER dated on 2019-02-20: Omeros Reports United States Adopted Names Council, International Nonproprietary Names Expert Committee Selected Name For Co.'s OMS721 As 'Narsoplimab'

Financial news for OMER dated on 2019-02-15: 71 Biggest Movers From Yesterday

Financial news for OMER dated on 2019-02-14: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for OMER dated on 2019-02-14: Omeros Corporation Streamlines Path To Biologics License Application For OMS721 In HSCT-TMA Following Meeting With FDA

Financial news for OMER dated on 2019-01-17: Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data

Financial news for OMER dated on 2019-01-17: Omeros Finalizes With FDA Clinical Plan For OMS721 Approval In IgA Nephropathy; Drug Appeared Well Tolerated With No Safety Concerns, Showed 61% Reduction In Proteinuria From Baseline

Financial news for OMER dated on 2019-01-16: 55 Biggest Movers From Yesterday

Financial news for OMER dated on 2019-01-15: 56 Biggest Movers From Yesterday

Financial news for OMER dated on 2019-01-14: 41 Stocks Moving In Monday's Mid-Day Session

Financial news for OMER dated on 2019-01-14: Omeros shares are trading higher after the company announced record high quarterly revenue in Q4.

Financial news for OMER dated on 2019-01-14: Omeros Reports Prelim. Q4 Total, OMIDRIA Sales At ~\$22M

Financial news for OMER dated on 2018-12-20: Omeros Establishes Independent Academic Leadership Committee For OMS721 Phase 3 Clinical Program In IgA Nephropathy

Financial news for OMER dated on 2018-12-11: Omeros Announces Research Collaboration With University Of Cambridge

Financial news for OMER dated on 2018-12-06: UPDATE: Omeros Says 'EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review'

Financial news for OMER dated on 2018-12-06: Omeros Announces Submission Of Pediatric Investigational Plan For The Use Of OMS721 In Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Financial news for OMER dated on 2018-11-12: 85 Biggest Movers From Friday

Financial news for OMER dated on 2018-11-09: Shares of Omeros Corp are trading down 22.3% after the company missed Q3 EPS estimates.

Financial news for OMER dated on 2018-11-09: 68 Stocks Moving In Friday's Mid-Day Session

Financial news for OMER dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for OMER dated on 2018-11-08: Omeros Q3 EPS \$(0.81) Misses \$(0.71) Estimate, Sales \$4.608M Beat \$3.19M Estimate

Financial news for OMER dated on 2018-10-23: Omeros's OMS721 for Treatment of Hematopoietic Stem Cell Transplant is Granted Orphan Drug Designation by the FDA

Financial news for OMER dated on 2018-10-03: 45 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-10-02: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Oct. 2, 2018

Financial news for OMER dated on 2018-10-02: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OMER dated on 2018-10-02: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OMER dated on 2018-10-02: 48 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-10-01: Omeros Shares Fall Over 40% On Renal Disease Trial Results

Financial news for OMER dated on 2018-10-01: Omeros Shares Halted On Circuit Breaker; The Stock Has Been Halted Multiple Times Today, Turn On Benzinga Signals To Be Alerted To All Halts And Resumptions

Financial news for OMER dated on 2018-10-01: Omeros Shares To Resume Trade At 2:45 p.m. ET, Down 5.1%

Financial news for OMER dated on 2018-10-01: 'So.. \$OMER '721 IGA nephropathy study failed but the company said the data were positive.... in the headline of the press release. Sure.....' -Tweet From STAT News' Adam Feuerstein

Financial news for OMER dated on 2018-10-01: Omeros Corporation Announces Additional Data For OMS721 In IgA Nephropathy; Says Drug Was Well-Tolerated And No Safety Concerns Were Seen In Cohort Of Patients

Financial news for OMER dated on 2018-10-01: Omeros Shares Halted, News Pending; Shares Down 5.1%

Financial news for OMER dated on 2018-10-01: Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA

Financial news for OMER dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for OMER dated on 2018-09-23: The Week Ahead In Biotech: Conferences,

PDUFA Dates, Clinical Trial Results And IPOs

Financial news for OMER dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for OMER dated on 2018-09-12: Jim Cramer Shares Thoughts On Skyworks Solutions, Cypress Semiconductor, More

Financial news for OMER dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for OMER dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for OMER dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for OMER dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for OMER dated on 2018-09-02: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for OMER dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for OMER dated on 2018-08-14: 55 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-08-13: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for OMER dated on 2018-08-13: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for OMER dated on 2018-08-13: 61 Biggest Movers From Friday

Financial news for OMER dated on 2018-08-10: 60 Stocks Moving In Friday's Mid-Day Session

Financial news for OMER dated on 2018-08-10: Omeros Corp. shares are trading 10% lower after the company announced lower-than-expected quarterly earnings per share and sales.

Financial news for OMER dated on 2018-08-09: Omeros Q2 EPS \$(0.70) Misses \$(0.62) Estimate, Sales \$1.655M Miss \$2.12M Estimate

Financial news for OMER dated on 2018-07-26: Omeros Reports Patent Infringement Suit Against Sandoz Related To ANDA To Market Generic Version Of OMIDRIA Was Dismissed By Stipulation Of Parties

Financial news for OMER dated on 2018-07-25: Omeros Reports OMS721 Received European Orphan Drug Designation For Treatment In Hematopoietic Stem Cell Transplantation

Financial news for OMER dated on 2018-07-23: Omeros to Begin Selling OMIDRIA in Europe

Financial news for OMER dated on 2018-07-17: Omeros Starts Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction, Nicotine Addiction Planned as First Indication; Completion Of Trial Expected First Half Of 2019

Financial news for OMER dated on 2018-06-27: Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment, First Clinical Target for PDE7 Inhibitor to be Nicotine Addiction

Financial news for OMER dated on 2018-05-31: '\$OMER says OMS721 deserves rapid approval for a deadly complication of bone marrow transplants b/c there are no approved treatments. But that's not true. An expert tells me \$ALXN Soliris works very well'

Financial news for OMER dated on 2018-05-31: Omeros Shares Quiet Premarket; STAT News' Adam Feuerstein Published Article 'Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws'

Financial news for OMER dated on 2018-05-17: Wedbush Maintains Neutral on Omeros, Raises Price Target to \$20

Financial news for OMER dated on 2018-05-17: 41 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-05-16: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for OMER dated on 2018-05-15: 48 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-05-14: 50 Biggest Movers From Friday

Financial news for OMER dated on 2018-05-11: 38 Stocks Moving In Friday's Mid-Day Session

Financial news for OMER dated on 2018-05-11: Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again

Financial news for OMER dated on 2018-05-10: Omeros Q1 EPS \$(0.62) Misses \$(0.43) Estimate, Sales \$1.588M Miss \$6.89M Estimate

Financial news for OMER dated on 2018-04-26: Omeros Reports FDA Breakthrough Therapy Designation For OMS721 For Treatment Of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Financial news for OMER dated on 2018-04-19: Omeros Reports Results Of 4 Studies Evaluating OMIDRIA Presented At ASCRS, ASOA Meetings

Financial news for OMER dated on 2018-04-11: 'Hey \$OMER -- Weren't we supposed to hear about breakthrough therapy status for OMS721 in HCT-TMA? But nice warrants.'-STAT's Adam Feuerstein Tweets

Financial news for OMER dated on 2018-03-27: 41 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-03-26: Omeros, Mattel, And 3 Other Stocks In Clear Trending Patterns This Week

Financial news for OMER dated on 2018-03-26: 42 Biggest Movers From Friday

Financial news for OMER dated on 2018-03-23: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for OMER dated on 2018-03-23: Benzinga's Top Upgrades, Downgrades For March 23, 2018

Financial news for OMER dated on 2018-03-23: Wedbush Downgrades Omeros to Neutral

Financial news for OMER dated on 2018-03-23: ICYMI: GameStop, Omeros, Congress Impacts Biotechs

Financial news for OMER dated on 2018-03-23: 41 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-03-22: Omeros Elevated By Medicare Reimbursement And OMS721 Progress, Says Maxim

Financial news for OMER dated on 2018-03-22: 28 Stocks Moving In Thursday's Mid-Day Session

Financial news for OMER dated on 2018-03-22: Mid-Day Market Update: Dow Falls Over 350 Points; Omeros Shares Spike Higher

Financial news for OMER dated on 2018-03-22: Biotech Winners And Losers From Congress' Latest Funding Bill

Financial news for OMER dated on 2018-03-22: Benzinga Pro's Top 10 Most-Searches Tickers Thurs., Mar. 22

Financial news for OMER dated on 2018-03-22: Benzinga Pro's 5 Stocks To Watch Today

Financial news for OMER dated on 2018-03-22: 21 Stocks Moving In Thursday's Pre-Market Session

Financial news for OMER dated on 2018-03-22: Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill

Financial news for OMER dated on 2018-03-22: Omeros Shares Up Nearly 30% Thurs. Following Favorable Determination In Latest Spending Package: 'an extra two years of charging Medicare higher prices for its cataract surgery drug'

Financial news for OMER dated on 2018-03-02: 32 Stocks Moving In Friday's Mid-Day Session

Financial news for OMER dated on 2018-03-02: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for OMER dated on 2018-03-01: Omeros Reports Q4 EPS \$(0.34) vs \$(0.14) Est., Sales \$13.8M vs \$23M Est.

Financial news for OMER dated on 2018-03-01: Adam Feuerstein Tweet: \$OMER, in its PR, basically admits Omidria sales have completely dried up in Q1 due to loss of pass-through status.

Financial news for OMER dated on 2018-02-27: Omeros Receives EU Orphan Drug Designation For OMS721

Financial news for OMER dated on 2018-02-23: 56 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-02-22: Adam Feuerstein Tweets: Here's the thing, Bill. \$OMER doesn't have multiple ph3 drugs. They have a single drug in a ph3 that isn't enrolling after more than a year, and a promise to start another ph3 based on data from 4 patients. Not great.

Financial news for OMER dated on 2018-02-15: Adam Feuerstein Tweets: \$OMER says nothing about Omidria sales cliff. Instead, pivots to touring a scientifically absurd OS analysis from a tiny, OMS721 single arm clinical trial.

Financial news for OMER dated on 2018-02-15: UPDATE: Omeros Highlights 'Greater than 16-Fold Improvement in Survival Compared to Historical Control'

Financial news for OMER dated on 2018-02-15: Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Financial news for OMER dated on 2018-02-15: 42 Biggest Movers From Yesterday

Financial news for OMER dated on 2018-02-14: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for OMER dated on 2018-02-14: Adam Feuerstein Tweets: \$OMER -17% on the highly critical report from FourWorld Capital. It's an informative read. Recommend. fourworldcapital.com/omer-download

Financial news for OMER dated on 2018-01-22: Omeros' OMS721 for Treatment of IgA Nephropathy Gets a Positive Opinion from the European Medicines Agency

Financial news for OMER dated on 2018-01-03: Stat News Reporter Adam Feuerstein Tweets: \$OMER OMS721 update in-line w/ expectations but what's the real status of the ph3 aHUS study? Any patients actually enrolled? Any timeline for completion? \$OMER doesn't like pesky questions.

Financial news for OMER dated on 2018-01-03: Omeros Reaches Agreement With FDA On Protocol For Its Phase 3 Trial Evaluating OMS721, Patient Enrollment To Begin Early Next Month

Financial news for OMER dated on 2017-12-12: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for OMER dated on 2017-12-12: Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use

Financial news for OMER dated on 2017-12-12: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OMER dated on 2017-12-12: Omeros Corporation Announces FDA Approval of OMIDRIA for Use in Pediatric Patients

Financial news for OMER dated on 2017-12-12: Omeros Reports FDA Approval Of OMIDRIA For Use In Pediatric Patients

Financial news for OMER dated on 2017-11-27: 32 Stocks Moving In Monday's Pre-Market Session

Financial news for OMER dated on 2017-11-13: 44 Biggest Movers From Friday

Financial news for OMER dated on 2017-11-10: Mid-Afternoon Market Update: Esterline Drops Following Downbeat Q4 Results; Alteryx Shares Jump

Financial news for OMER dated on 2017-11-10: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for OMER dated on 2017-11-10: Mid-Day Market Update: Omeros Climbs After Strong Q3 Results; LightPath Technologies Shares Plunge

Financial news for OMER dated on 2017-11-10: Can Omeros Top-Line Growth Continue?

Financial news for OMER dated on 2017-11-10: Mid-Morning Market Update: Markets Open Lower; J C Penney Sales Beat Estimates

Financial news for OMER dated on 2017-11-10: 31 Stocks Moving In Friday's Pre-Market Session

Financial news for OMER dated on 2017-11-09: Omeros Reports Q3 EPS \$(0.16) vs \$(0.33) Est.

Financial news for OMER dated on 2017-11-08: Benzinga's Top Upgrades, Downgrades For November 8, 2017

Financial news for OMER dated on 2017-11-08: H.C. Wainwright Initiates Coverage On Omeros with Buy Rating, Announces \$30.00 Price Target

Financial news for OMER dated on 2017-11-06: Omeros Option Alert: Jan, 2019 \$17 Calls at the Ask: 1500 @ \$4.0 vs 48 OI; Ref=\$13.8

Financial news for OMER dated on 2017-11-06: Omeros Option Alert: Jan, 2019 \$17 Calls at the Ask: 1000 @ \$4.0 vs 48 OI; Ref=\$13.85

Financial news for OMER dated on 2017-11-06: Omeros Reports Extended Follow-Up Data From Patients With IgA Nephropathy Treated With OMS721 Presented At ASN Nov. 4

Financial news for OMER dated on 2017-11-02: Adam Feuerstein Tweets: \$OMER Omidria losing Medicare pass-through code, so price will fall a lot. Funny, this is one of risks shorts warned about ahead of time.

Financial news for OMER dated on 2017-11-02: Cowen & Co. Downgrades Omeros to Market Perform

Financial news for OMER dated on 2017-11-02: Hearing Cowen Downgrades Omeros From Outperform To Market Perform

Financial news for OMER dated on 2017-10-30: Omeros Shares Continue Higher Mon., Up 9.4%, Following 12% Rally On Fri. Amid News Of 'Substantial, Significant' Improvements In TMA Activity During Phase 2 Trial Of OMS721

Financial news for OMER dated on 2017-10-26: Omeros Reports Substantial, Significant Improvement Markers of TMA Activity Were Seen In Expanded Number Of Study Patients In Phase 2 OMS721 Trial, Prepares To Begin Phase 3 Clinical Trial

Financial news for OMER dated on 2017-10-25: 40 Biggest Movers From Yesterday

Financial news for OMER dated on 2017-10-24: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Polaris Shares Surge On Upbeat Earnings

Financial news for OMER dated on 2017-10-24: Mid-Day Market Update: Dow Rises 175 Points; Identiv Shares Plunge

Financial news for OMER dated on 2017-10-24: Mid-Morning Market Update: Markets Open Higher; General Motors Profit Tops Expectations

Financial news for OMER dated on 2017-10-20: STAT News Adam Feuerstein '\$OMER presented a patient anecdote instead of real clinical trial data at a medical meeting. Still won't answer questions.'

Financial news for OMER dated on 2017-10-20: UPDATE: Omeros Says Results From OMS721 Trial 'May Expand Target for Omeros' Planned Phase 3 Program in HCT-TMA'

Financial news for OMER dated on 2017-10-20: Omeros Reports Successful OMS721 Treatment Of Patient With Both Stem Cell Transplant-Associated Thrombotic Microangiopathy And Graft-Versus-Host Disease

Financial news for OMER dated on 2017-10-05: Omeros Reports Settlement Of Infringement Suit Against Par

Financial news for OMER dated on 2017-08-31: Benzinga's Option Alert Recap From August 31

Financial news for OMER dated on 2017-08-31: Omeros Spikes to High of \$20.76 on Volume

Financial news for OMER dated on 2017-08-31: Omeros Option Alert: Sep 15 \$23 Puts Sweep (30) at the Bid: 603 @ \$2.952 vs 171 OI; Ref=\$20.26

Financial news for OMER dated on 2017-08-24: 25 Stocks Moving In Thursday's Pre-

Market Session

Financial news for OMER dated on 2017-08-23: STAT News' Adam Feuerstein Tweets '\$OMER defends its drug, but still won't answer basic questions'

Financial news for OMER dated on 2017-08-22: STAT News' Adam Feuerstein Tweets '\$OMER doesn't answer same questions when asked by analysts or institutional investors. Strange, eh?'

Financial news for OMER dated on 2017-08-15: 18 Biggest Mid-Day Losers For Tuesday

Financial news for OMER dated on 2017-08-15: Omeros Prices 3M Shares At \$22.75/Share

Financial news for OMER dated on 2017-08-15: Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet

Financial news for OMER dated on 2017-08-15: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OMER dated on 2017-08-14: Omeros Announces 3M Share Offering Common Stock

Financial news for OMER dated on 2017-08-14: Omeros Reports Data On Patients With IgA Nephropathy Treated With OMS721: 'Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data'

Financial news for OMER dated on 2017-08-08: Omeros Reports Q2 GAAP EPS \$(0.33) vs \$(0.32) In Same Qtr. Last Year, Sales \$17.2M

Financial news for OMER dated on 2017-08-04: FDA Grants Orphan Drug Designation to Omeros' OMS721, Initiating Phase 3 Program for OMS721 in IgA Nephropathy with Both Breakthrough and Orphan Designations

Financial news for OMER dated on 2017-07-10: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for OMER dated on 2017-07-07: Benzinga's Option Alert Recap From July 7

Financial news for OMER dated on 2017-07-07: Option Alert: Omeros Nov 12.0 Puts Sweep: 667 @ ASK \$0.80: 700 traded vs 133 OI: Earnings 8/9 After Close (est) \$18.97 Ref

Financial news for OMER dated on 2017-06-29: UPDATE: Omeros On Art Doyle Report: 'The report is actionable and the company is pursuing legal remedies. Omeros intends to hold all responsible parties accountable'

Financial news for OMER dated on 2017-06-29: UPDATE: Omeros On Art Doyle Report: 'This report is replete with falsehoods, misleading statements and incorrect analyses and conclusions'

Financial news for OMER dated on 2017-06-29: Omeros Offers Statement Following Recent False Report

Financial news for OMER dated on 2017-06-28: Omeros Shares Fall Just After Open, Now Down 1.8% As Traders Circulating Tuesday Short Report From Art Doyle As If It Is New Today; Stock Now Bouncing Off Session Lows

Financial news for OMER dated on 2017-06-23: Mid-Afternoon Market Update: Portola Climbs On FDA Approval For Bevyxxa; American Software Shares Plunge

Financial news for OMER dated on 2017-06-23: Martin Shkreli In Facebook Post On Omeros Says: 'Take profits \$OMER and don't forget to say thank you'

Financial news for OMER dated on 2017-06-22: 8K Filing From Omeros Shows Co. Files Patent Infringement Suit Against Sandoz

Financial news for OMER dated on 2017-06-14: 2 Longs And 2 Shorts To Watch

Financial news for OMER dated on 2017-06-13: Cantor Fitzgerald's Piros Still Isn't A Buyer Of Omeros After Tuesday's FDA Win

Financial news for OMER dated on 2017-06-13: Omeros Reports FDA Granted Breakthrough Designation For OMS721 For Treatment Of IgA Nephropathy

Financial news for OMER dated on 2017-05-17: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for OMER dated on 2017-05-17: Omeros Completes Phase 2 Trial

Financial news for OMER dated on 2017-05-11: Cantor Fitzgerald Downgrades Omeros To Neutral, Lowers Price Target To \$15

Financial news for OMER dated on 2017-05-10: Omeros Reports Q1 EPS \$(0.34) vs \$(0.35) Est., Sales \$12.257M vs \$13.32M Est.

Financial news for OMER dated on 2017-04-04: The Latest Top Hot Short Ideas: Sears And Credit Acceptance

Financial news for OMER dated on 2017-03-30: 15 Biggest Mid-Day Gainers For Thursday

Financial news for OMER dated on 2017-03-30: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for OMER dated on 2017-03-30: UPDATE: Omeros Reports New Data 'corroborate and expand on trial results reported in Q4'16'

Financial news for OMER dated on 2017-03-30: Omeros Reports Data in OMS721 Phase 2 Trial in Renal Diseases

Financial news for OMER dated on 2017-03-28: 20 Biggest Mid-Day Gainers For Tuesday

Financial news for OMER dated on 2017-03-28: Omeros Rallies After OMS721 Presentation

Financial news for OMER dated on 2017-03-20: 12 Biggest Mid-Day Gainers For Monday

Financial news for OMER dated on 2017-03-20: Omeros Pops to High of \$11.86 on Volume

Financial news for OMER dated on 2017-03-16: Omeros Reports Q4 EPS \$(0.45) vs \$(0.56) Est., Sales \$12.9M vs \$12.5M Est.

Financial news for OMER dated on 2017-03-16: Earnings Scheduled For March 16, 2017

Financial news for OMER dated on 2017-02-09: Omeros Shorts Are Feeling The Heat

Financial news for OMER dated on 2017-02-07: Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Financial news for OMER dated on 2017-01-03: 13 Emerging Biotechs With Catalysts In 2017

Financial news for OMER dated on 2016-12-07: Data from Omeros' OMS721 Phase 2 Clinical Trial in Patients with Stem Cell Transplant-Associated TMA to be Presented at International Transplant Conference

Financial news for OMER dated on 2016-11-30: Omeros Wins EUR 1.3M Grant to Study the Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury

Financial news for OMER dated on 2016-11-21: Omeros Announces Outcome of OMIDRIA Pediatric Cataract Trial

Financial news for OMER dated on 2016-11-10: 18 Biggest Mid-Day Gainers For Thursday

Financial news for OMER dated on 2016-11-10: Mid-Day Market Update: NASDAQ Down Over 1%; TubeMogul Shares Surge Following Acquisition News

Financial news for OMER dated on 2016-11-10: Omeros Up 18+% After Positive Results in MASP-3 Inhibitor OMS906 Study, Showed Sustained Ablation of APC Activity for ~16 Days; Preparing for Clinical Trials

Financial news for OMER dated on 2016-11-10: Mid-Morning Market Update: Markets Open Higher; Ralph Lauren Profit Tops Views

Financial news for OMER dated on 2016-11-10: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for OMER dated on 2016-11-09: Omeros Corp. Reports Q3 EPS \$(0.34) vs \$(0.40) Est.

Financial news for OMER dated on 2016-11-09: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for OMER dated on 2016-11-09: 10 Stocks That Rallied Four Days, Then Sold Off Yesterday

Financial news for OMER dated on 2016-11-08: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OMER dated on 2016-11-07: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for OMER dated on 2016-11-04: Technical Alert: Omeros Corporation Higher For Fourth Day In A Row

Financial news for OMER dated on 2016-11-04: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for OMER dated on 2016-11-03: 20 Biggest Mid-Day Gainers For Thursday

Financial news for OMER dated on 2016-11-03: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for OMER dated on 2016-11-03: Omeros Files Orphan Drug Application for OMS721 in Immunoglobulin A Nephropathy

Financial news for OMER dated on 2016-11-02: 22 Biggest Mid-Day Gainers For Wednesday

Financial news for OMER dated on 2016-11-02: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for OMER dated on 2016-11-02: Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist in Heroin Users Treated with Buprenorphine/Naloxone

Financial news for OMER dated on 2016-11-01: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OMER dated on 2016-10-31: 15 Biggest Mid-Day Gainers For Monday

Financial news for OMER dated on 2016-10-31: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for OMER dated on 2016-10-31: Omeros Requests Fast Track Designation for OMS721 for the Treatment of IgA Nephropathy

Financial news for OMER dated on 2016-10-27: Omeros Earlier Announced \$125 Million New Credit Facility

Financial news for OMER dated on 2016-10-24: 10 Stocks Which Rallied Three Days On Increasing Volume

Financial news for OMER dated on 2016-10-20: Omeros Stock Remains Higher On Promising Kidney Drug Trial Data

Financial news for OMER dated on 2016-10-20: Mid-Day Market Update: Insteel Industries Drops Following Q4 Results; DragonWave Shares Spike Higher

Financial news for OMER dated on 2016-10-20: Omeros Finds Buyers In The \$7 Handle Again

Financial news for OMER dated on 2016-10-20: UPDATE: Omeros Says No Significant Safety Concerns Have Been Observed

Financial news for OMER dated on 2016-10-20: Omeros Reports Data from OMS721 Phase 2 Trial Showed 'Targeted Indications for the Company's MASP-2 Inhibitor Continue to Expand'

Financial news for OMER dated on 2016-10-19: 16 Stocks Moving In Wednesday's Pre-Market Session

Financial news for OMER dated on 2016-10-19: Omeros Calls New Phase 2 Data For PPAR Positive

Financial news for OMER dated on 2016-10-17: 15 Biggest Mid-Day Gainers For Monday

Financial news for OMER dated on 2016-10-17: Selling The News In Omeros

Financial news for OMER dated on 2016-10-17: Mid-Morning Market Update: Markets Edge Lower; Bank of America Profit Tops Views

Financial news for OMER dated on 2016-10-17: Omeros Stock Lifted By Positive Phase 2 Clinical Data

Financial news for OMER dated on 2016-10-17: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for OMER dated on 2016-10-17: Omeros +8.7% Premarket at \$7.98; Co

Announced Positive Data from Phase 2 Trial for Treatment of Kidney Disorders

Financial news for OMER dated on 2016-10-14: Mid-Day Market Update: Advanced Micro Devices Climbs After Chip Deal With Alibaba; Ocean Power Technologies Shares Slide

Financial news for OMER dated on 2016-10-12: Mid-Afternoon Market Update: Crude Oil Down Over 1%; VOXX Shares Spike Higher

Financial news for OMER dated on 2016-10-06: 7 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for OMER dated on 2016-10-05: 10 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for OMER dated on 2016-08-11: 20 Biggest Mid-Day Losers For Thursday

Financial news for OMER dated on 2016-08-11: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for OMER dated on 2016-08-10: Omeros Announces Public Offering of Common Stock \$40M

Financial news for OMER dated on 2016-08-10: Omeros Reports OMS906 Showed Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model

Financial news for OMER dated on 2016-08-09: Omeros Corp. Reports Q2 EPS \$(0.32) vs. Est. \$(0.50), Rev. \$10M vs. Est. \$9.24M

Financial news for OMER dated on 2016-06-29: Omeros Reports Closing of Patient Enrollment in Pediatric Trial of OMIDRIA

Financial news for OMER dated on 2016-06-03: Cantor Fitzgerald Starts Omeros With Buy, \$21PT

Financial news for OMER dated on 2016-06-02: Cantor Fitzgerald Initiates Coverage on Omeros at Buy, Announces \$21.00 PT

Financial news for OMER dated on 2016-05-23: Omeros Sells off to Low of \$18.20 on Vol

Financial news for OMER dated on 2016-05-10: Mid-Day Market Update: Sodastream Gains Following Earnings Beat; NewLink Genetics Shares Decline

Financial news for OMER dated on 2016-05-10: Mid-Morning Market Update: Markets Open Higher; Allergan Earnings Top Views

Financial news for OMER dated on 2016-05-10: Omeros Reports Q1 EPS \$(0.54) vs \$(0.43) Est., Sales \$7.4M vs \$8.8M Est.

Financial news for OMER dated on 2016-05-10: Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA

Financial news for OMER dated on 2016-05-10: Omeros Announces Exclusive Middle East Distribution Agreement for OMIDRIA

Financial news for OMER dated on 2016-04-20: Omeros Reports Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases

Financial news for OMER dated on 2016-04-12: Roth Capital Terminates Buy Rating on Omeros, Removes \$38.00 PT

Financial news for OMER dated on 2016-03-08: Benzinga's Volume Movers

Financial news for OMER dated on 2016-03-08: Omeros Reports Initiation of Phase 3 Program for OMS721 in aHUS Following FDA Meeting, Says Single Pivotal Study Needed for Phase 3

Financial news for OMER dated on 2016-03-08: Earnings Scheduled For March 8, 2016

Financial news for OMER dated on 2016-03-07: Omeros Corp Reports Q4 EPS \$(0.52) Vs Est \$(0.55), Sales \$6.675M Vs Est \$5.35M

Financial news for OMER dated on 2016-01-02: Every Biotech Catalyst Wedbush Is Watching In 2016

Financial news for OMER dated on 2015-12-18: Omeros Spikes Higher

Financial news for OMER dated on 2015-11-19: 9 IPOs That Fell Flat On Wall Street

Financial news for OMER dated on 2015-11-09: Omeros Reports Q3 EPS (\$0.53) Vs Est

(\$0.47), Sales \$3.26M Vs Est \$7.20M

Financial news for OMER dated on 2015-10-15: Omeros Announces OMIDRIAssure(tm) to Expand Patient Access to Omidria(r)

Financial news for OMER dated on 2015-09-03: Omeros Files Infringement Suits Against Par

Financial news for OMER dated on 2015-09-01: Omeros Receives Patent for Use of PDE7 Inhibitors for Treatment of Movement Disorders

Financial news for OMER dated on 2015-08-26: Where Is Omeros Corporation Now?

Financial news for OMER dated on 2015-08-18: Omeros Corporation: Another Biotech Bubble In The Making?

Financial news for OMER dated on 2015-08-18: Mid-Day Market Update: Tuesday's Top 10 Volume Stocks

Financial news for OMER dated on 2015-08-18: Mid-Day Market Update: National Penn Bancshares Surges On Acquisition News; Vera Bradley Shares Slide

Financial news for OMER dated on 2015-08-18: Mid-Day Market Update: Tuesday's Movers, China's Growth Worries And More

Financial news for OMER dated on 2015-08-18: Mid-Morning Market Update: Markets Open Lower; Wal-Mart Lowers Full-Year Forecast

Financial news for OMER dated on 2015-08-18: Benzinga's Volume Movers

Financial news for OMER dated on 2015-08-18: Morning Market Gainers

Financial news for OMER dated on 2015-08-18: UPDATE: Omeros +68% Premarket Following Announcement of Additional Positive Data in OMS721 Phase 2 Clinical Trial

Financial news for OMER dated on 2015-08-18: Benzinga's Top #PreMarket Gainers

Financial news for OMER dated on 2015-08-18: Omeros +22% Premarket Following Announcement of Additional Positive Data in OMS721 Phase 2 Clinical Trial

Financial news for OMER dated on 2015-08-18: UPDATE: Omeros Provides Phase 2 Study Update

Financial news for OMER dated on 2015-08-18: Omeros Provides Phase 2 Study Update

Financial news for OMER dated on 2015-08-17: Omeros Announces Plans to file Patent Suit Against Par Pharma

Financial news for OMER dated on 2015-08-10: Omeros Corp. Reports Q2 EPS \$(0.44) vs. Est. \$(0.56), Rev. \$3.2M vs. Est. \$2.86M

Financial news for OMER dated on 2015-08-10: Benzinga's Top Initiations

Financial news for OMER dated on 2015-08-10: Roth Capital Initiates Coverage on Omeros at Buy, Announces \$38.00 PT

Financial news for OMER dated on 2015-07-23: Omeros Announces FDA Grants Fast Track Designation to Complement Inhibitor OMS721 for aHUS

Financial news for OMER dated on 2015-07-02: Watch Shares of Omeros Here as Wedbush's Liana Moussatos Saying Buy the Dip Given 'Potential 2015 Catalysts,' Outperform Rating, \$61 Price Target Reiterated

Financial news for OMER dated on 2015-06-16: Omeros Corp. Enters Licensing Agreement With Affiliates Of Fagron NV Product OMS103

Financial news for OMER dated on 2015-05-22: Omidria Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use

Financial news for OMER dated on 2015-05-11: Omeros Reports Q1 Loss \$0.51 Vs Est Loss \$0.63, Sales \$388K

Financial news for OMER dated on 2015-04-14: Omeros Announces European Regulatory Authority Approves Compassionate Use for OMS721

Financial news for OMER dated on 2015-04-02: Omeros Corp. Launches Omidria In U.S.

Financial news for OMER dated on 2015-03-16: UPDATE: Omeros Beats Q4 Estimates

Financial news for OMER dated on 2015-03-16: Omeros Corp. Reports Q4 EPS \$(0.61) vs. Est. \$(0.62), Rev. \$180K Vs. Est \$90K

Financial news for OMER dated on 2015-03-16: Earnings Scheduled For March 16, 2015

Financial news for OMER dated on 2015-03-02: Benzinga's Volume Movers

Financial news for OMER dated on 2015-02-19: Omeros Corporation Announces Phase 2 OMS721 Trial Results in Extended Access for Compassionate Use

Financial news for OMER dated on 2015-02-03: Omeros Closes \$84M Public Offering

Financial news for OMER dated on 2015-01-29: Omeros Prices \$75M Public Offering of Common Stock and Pre-Funded Warrants

Financial news for OMER dated on 2015-01-28: Omeros Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants

Financial news for OMER dated on 2015-01-28: Omeros Files for Potential Stock Offering; Size Not Disclosed

Financial news for OMER dated on 2015-01-16: Filing from Omeros Shows Registration for Automatic Mixed Securities Shelf Offering

Financial news for OMER dated on 2014-11-19: Omeros Reports OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients

Financial news for OMER dated on 2014-11-18: Mid-Day Market Update: SunEdison, TerraForm Jump On First Wind Acquisition; TJX Shares Drop

Financial news for OMER dated on 2014-11-13: The Top 25 Analysts On Wall Street

Financial news for OMER dated on 2014-11-06: US Stock Futures Edge Lower Ahead Of Earnings, Jobless Claims

Financial news for OMER dated on 2014-11-06: Omeros Announces Positive Data For MASP-2 Inhibitor In Experimental Model Of Stroke

Financial news for OMER dated on 2014-10-30: Omeros Corporation Announces It Has Received Transitional Pass-through Status For Omidria

Financial news for OMER dated on 2014-10-21: Morning Market Losers

Financial news for OMER dated on 2014-10-21: Benzinga's Top #PreMarket Losers

Financial news for OMER dated on 2014-10-21: Omeros Provides Update on PDE10 Inhibitor Program

Financial news for OMER dated on 2014-08-11: Omeros Corporation Reports Q2 EPS of \$(0.53) Which May Not Compare \$(0.52) Est

Financial news for OMER dated on 2014-06-02: Morning Market Movers

Financial news for OMER dated on 2014-06-02: Omeros Shares Resume Trading Up 11% Following Report of FDA Approval of Omidria

Financial news for OMER dated on 2014-06-02: Benzinga's Top #PreMarket Gainers

Financial news for OMER dated on 2014-06-02: Omeros Receives FDA Approval of Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures

Financial news for OMER dated on 2014-05-22: Form 8-K from Omeros Shows Pact with Inventiv, Co. Will Pay Inventiv Fees

Financial news for OMER dated on 2014-05-12: Omeros Corporation Reports Q1 EPS of \$(0.54) vs \$(0.45) Est

Financial news for OMER dated on 2014-04-03: US Stock Futures Edge Higher Ahead Of Jobless Claims Data

Financial news for OMER dated on 2014-04-03: Omeros Announces IND Cleared by FDA for OMS721 in Thrombotic Microangiopathies

Financial news for OMER dated on 2014-04-01: Omeros to Make Presentation on OMS824 Phase 2 Clinical Program at Schizophrenia International Research Conference

Financial news for OMER dated on 2014-03-14: Omeros Prices 3M Shares at \$11.50/Share

Financial news for OMER dated on 2014-03-13: Omeros Announces Offering of Common

Shares

Financial news for OMER dated on 2014-03-13: Omeros Announces Proposed Public Offering of Common Stock

Financial news for OMER dated on 2014-03-13: Omeros Corporation Reports Q4 EPS of \$(0.46) vs \$(0.38) Est

Financial news for OMER dated on 2014-03-10: Omeros Reports Positive OMS721 Data in Serum from Patients with aHUS

Financial news for OMER dated on 2014-03-06: Omeros Announces Additional Positive Data from OMS824 Phase 2a Schizophrenia Clinical Trial

Financial news for OMER dated on 2014-03-04: Omeros Submits IND to FDA for Advance OMS721 Phase 2 Clinical Program

Financial news for OMER dated on 2014-02-11: McNicoll Lewis Vlak Maintains Buy on Omeros Corporation, Raises PT to \$19.00

Financial news for OMER dated on 2014-02-05: Benzinga's Top #PreMarket Gainers

Financial news for OMER dated on 2014-02-05: Omeros Receives FDA Fast Track Designation for OMS824 Huntington's Disease Program

Financial news for OMER dated on 2014-02-03: Omeros Announces Positive Data for Phase 1 Clinical Trial with OMS721

Financial news for OMER dated on 2014-01-29: UPDATE: Omeros Announces Positive OMS824 Phase 2a Clinical Trial Results

Financial news for OMER dated on 2014-01-29: Omeros Reports Positive Results From OMS824 Phase 2a Clinical Trial

Financial news for OMER dated on 2013-12-18: Benzinga's Top #PreMarket Gainers

Financial news for OMER dated on 2013-12-18: UPDATE: FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated Thrombotic Microangiopathies

Financial news for OMER dated on 2013-12-16: Hearing Wedbush Names Omeros Top Pick for 2014; \$32 PT

Financial news for OMER dated on 2013-11-20: Omeros Announces FDA Accepts Omidria as Brand Name for OMS302

Financial news for OMER dated on 2013-11-19: Omeros Presents Phase 3 OMS302 Clinical Data Annual American Academy of Ophthalmology Meeting

Financial news for OMER dated on 2013-11-05: Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration

Financial news for OMER dated on 2013-11-05: Omeros Reports Positive OMS721 Data

Financial news for OMER dated on 2013-10-15: Omeros Says FDA Has Agreed to Pediatric Study Plan for OMS302

Financial news for OMER dated on 2013-10-03: Benzinga's Top Pre-Market Gainers

Financial news for OMER dated on 2013-10-03: Omeros Identifies Six Additional Class A Orphan GPCRs

Financial news for OMER dated on 2013-10-02: Shares Of Omeros Rocket Higher As Wedbush Lifts Target, Sees Near Tripling In Stock Price

Financial news for OMER dated on 2013-10-02: Omeros Spikes Higher; May be Attributed to Wedbush Raising PT to \$32

Financial news for OMER dated on 2013-10-02: FDA, EMA Accept OMS302 Marketing Applications for Review

Financial news for OMER dated on 2013-09-30: Omeros Announces FDA Orphan Drug Designation for OMS824 for Huntington's Disease

Financial news for OMER dated on 2013-09-27: Bloomberg Reporting Omeros Wins Orphan Drug Designation for Huntington's Disease Treatment

Financial news for OMER dated on 2013-09-19: Omeros Initiates Phase 2 Clinical Trial with OMS824

Financial news for OMER dated on 2013-09-17: Benzinga's Top Pre-Market Losers

Financial news for OMER dated on 2013-09-16: Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use

Financial news for OMER dated on 2013-09-16: Shares of Omeros Rocket Higher (43%), Wedbush's Moussatos Says OMS302 Could Benefit from FDA Restrictions on Topical Solutions in Intraocular Lens Replacement Surgery, Boosted Target from \$18 to \$28, Outperform Maintained

Financial news for OMER dated on 2013-09-16: Morning Market Movers

Financial news for OMER dated on 2013-09-12: Omeros Reports Additional Positive Results from Phase 1 OMS824 Clinical Trial

Financial news for OMER dated on 2013-08-13: Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer

Financial news for OMER dated on 2013-08-12: Shares of Omeros Bounce Over \$5.40 Following Mid-Day Comments from MLV's Zavoico

Financial news for OMER dated on 2013-08-09: Omeros Corporation Reports Q2 EPS of \$(0.48) vs \$(0.38) Est

Financial news for OMER dated on 2013-08-01: Omeros Submits NDA for OMS302, Wedbush Says Approval Could be 'Catalyst' for Stock

Financial news for OMER dated on 2013-08-01: Omeros Spikes Higher, May be Attributed to Positive Wedbush Note

Financial news for OMER dated on 2013-07-02: European Medicines Agency Approves Positive Opinion on Omeros' Pediatric Investigation Plan for OMS302

Financial news for OMER dated on 2013-05-31: A Peek Into The Market Before The Trading Starts

Financial news for OMER dated on 2013-05-31: Omeros Announces Positive Results from OMS824 Positron Emission Tomography Trial

Financial news for OMER dated on 2013-05-28: Omeros Files Clinical Trial Application with CTA for Lead Antibody in MASP-2 Program

Financial news for OMER dated on 2013-05-23: Omeros Announces IND for OMS824 in Huntington's Disease Cleared by FDA

Financial news for OMER dated on 2013-05-14: Traders in Omeros Attributing Upside in Shares to Bullish Note from MLV & Co., Says Trend Higher 'Will Continue'

Financial news for OMER dated on 2013-05-10: Omeros Corporation Reports Q1 EPS of \$(0.40), Inline; Revenue of \$1.10M vs \$1.39M Est

Financial news for OMER dated on 2013-05-09: Omeros Announces 3.9M Share Direct Offering of Common Stock at \$4.14/Share

Financial news for OMER dated on 2013-04-18: WBB Pounds the Table on Omeros Following Orphan Drug Status, Maintains Strong Buy Rating, \$20 Target

Financial news for OMER dated on 2013-04-17: Omeros Files Orphan Drug Application with FDA for OMS721

Financial news for OMER dated on 2013-04-15: MLV & Co. Initiates Coverage on Omeros Corporation at Buy, Announces \$14.00 PT

Financial news for OMER dated on 2013-04-10: Omeros Announces Positive Data for Model for Studying Multiple Sclerosis

Financial news for OMER dated on 2013-04-02: Omeros Announces Positive OMS721 Data

Financial news for OMER dated on 2013-03-28: A Peek Into The Market Before The Trading Starts

Financial news for OMER dated on 2013-03-28: Omeros Announces Toxicology Data from OMS721 Study Support Advancing MASP-2 Inhibitor into Clinical Trials

Financial news for OMER dated on 2013-03-26: Stocks Hitting 52-Week Lows

Financial news for OMER dated on 2013-03-26: Omeros Completes PDE10 Phase 1 Multiple Ascending Dose Trial

Financial news for OMER dated on 2013-03-21: Stocks Hitting 52-Week Lows

Financial news for OMER dated on 2012-12-28: UPDATE: Canaccord Genuity Cuts PT to \$13 on Omeros Corporation on Phase 3 Endpoint Miss

Financial news for OMER dated on 2012-12-28: UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Omeros Corporation

Financial news for OMER dated on 2012-12-28: Canaccord Genuity Maintains Buy on Omeros Corporation, Lowers PT to \$13.00

Financial news for OMER dated on 2012-12-28: Deutsche Bank Maintains Buy on Omeros Corporation, Lowers PT to \$10.00

Financial news for OMER dated on 2012-12-28: Stocks To Watch For December 28, 2012

Financial news for OMER dated on 2012-12-27: Omeros Shares to Resume Trading at 4:30PM EST

Financial news for OMER dated on 2012-12-27: Omeros Announces Phase 3 Results on OMS103HP, Says Symptoms Subscale Didn't Meet Statistical Significance

Financial news for OMER dated on 2012-12-06: Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program

Financial news for OMER dated on 2012-12-06: Omeros Announces Promising Data from Phase 1 OMS824 Clinical Trial

Financial news for OMER dated on 2012-12-04: From Earlier: Needham Upgrades Omeros Corporation to Buy, Announces \$10.00 PT

Financial news for OMER dated on 2012-11-09: Omerosorotion Reports Q3 EPS \$-0.51 vs \$-0.34 Est; Revenues \$1.41M vs \$1.42M Est

Financial news for OMER dated on 2012-11-09: Omeros Responds to Misleading Announcement Concerning Settlement with Former CFO Richard J. Klein

Financial news for OMER dated on 2012-11-05: Wedbush Securities Maintains Omerosorotion at Outperform, Raises PT from \$19 to \$20

Financial news for OMER dated on 2012-11-05: Omeros' Ophthalmology Announces Clinical Trial Data

Financial news for OMER dated on 2012-10-15: UPDATE: Burrill Research Initiates Omeros Corporation at Market Outperform on Pipeline Strength

Financial news for OMER dated on 2012-10-15: Burrill Research Initiates Coverage on Omerosorotion at Market Outperform, Announces PT of \$17

Financial news for OMER dated on 2012-10-02: From Earlier: Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program

Financial news for OMER dated on 2012-09-06: Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program

Financial news for OMER dated on 2012-08-15: Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs

Financial news for OMER dated on 2012-07-18: Wedbush Securities Maintains Omerosorotion at Outperform, Raises PT from \$18 to \$19

Financial news for OMER dated on 2012-07-18: Wedbush Securities Maintains Omerosorotion at Outperform, Raises PT from \$18 to \$19

Financial news for OMER dated on 2012-07-18: Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway

Financial news for OMER dated on 2012-06-27: Wedbush Securities Maintains Omeros Corporation at Outperform, Lowers PT from \$20 to \$18

Financial news for OMER dated on 2012-06-27: Omeros Down Nearly 20% After Pricing 3M Share Secondary

Financial news for OMER dated on 2012-06-27: Omeros Prices \$30M Public Offering of Common Stock at \$10.25 per Share

Financial news for OMER dated on 2012-06-27: Benzinga's Top Pre-Market Losers

Financial news for OMER dated on 2012-06-26: Omeros Announces Proposed Public Offering of Common Stock

Financial news for OMER dated on 2012-05-31: Omeros Announces Initiation of Planned Pharmacokinetic Substudy in OMS302 Phase 3 Clinical Program

Financial news for OMER dated on 2012-04-10: Omeros Announces Enrollment in Second Phase 3 Clinical Trial Evaluating OMS302

Financial news for OMER dated on 2012-03-29: A Peek Into The Market Before The Trading Starts

Financial news for OMER dated on 2012-03-29: Omeros Reports Allowance of Additional Patent for Ophthalmology Product OMS302

Financial news for OMER dated on 2012-03-14: UPDATE: Deutsche Bank Upgrades Omeros

Financial news for OMER dated on 2012-03-14: UPDATE: Canaccord Upgrades Omeros; Raises PT

Financial news for OMER dated on 2012-03-14: Canaccord Upgrades Omeros from Hold to Buy, Raises PT from \$5 to \$13

Financial news for OMER dated on 2012-03-13: UPDATE: Rodman & Renshaw Raises PT to \$16 on Omeros Corporation

Financial news for OMER dated on 2012-03-13: Wedbush Securities Maintains Omeros at Outperform, Raises PT from \$15 to \$17

Financial news for OMER dated on 2012-03-13: Rodman & Renshaw Maintains Omeros at Market Outperform, Raises PT from \$13 to \$16

Financial news for OMER dated on 2012-03-13: Deutsche Bank Upgrades Omeros from Hold to Buy, Raises PT from \$6 to \$11

Financial news for OMER dated on 2012-03-13: Omeros' Ophthalmology Product OMS302 Achieves Primary and Secondary Endpoints in Phase 3 Clinical Trial

Financial news for OMER dated on 2012-03-13: Omeros Rises 41% on Positive Phase 3 Results

Financial news for OMER dated on 2012-03-12: Earnings Scheduled For March 12

Financial news for OMER dated on 2012-03-06: Omeros Trading 6.9% Higher on Heavy Volume; Currently at \$8.35

Financial news for OMER dated on 2012-02-21: Omeros Awarded \$1 Million NIDA Grant for NMUR2 Drug Development Program

Financial news for OMER dated on 2012-02-07: Omeros Provides Update on Ongoing OMS302 Phase 3 Clinical Trial

Financial news for OMER dated on 2012-01-10: Benzinga's Microcap Movers for Tuesday January 10, 2012

Financial news for OMER dated on 2011-12-05: UPDATE: Rodman & Renshaw Upgrades Omeros to Outperform

Financial news for OMER dated on 2011-12-05: Rodman & Renshaw Upgrades Omeros to Market Outperform, \$13 PT

Financial news for OMER dated on 2011-11-30: UPDATE: Wedbush Raises PT to \$15 on Omeros Corp

Financial news for OMER dated on 2011-11-30: Wedbush Raises PT on Omeros to \$15

Financial news for OMER dated on 2011-10-11: Rodman & Renshaw Maintains Market Perform on Omeros Corp

Financial news for OMER dated on 2011-10-11: Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302

Financial news for OMER dated on 2011-05-31: Omeros Unlocks Orphan GPCR Family Linked to Metabolic and Psychotic Disorders

Financial news for OMER dated on 2011-04-01: Omeros Corporation Plummets 34.50% (OMER)

Financial news for OMER dated on 2011-04-01: Deutsche Bank Downgrades OMER To Hold

Financial news for OMER dated on 2011-03-24: Deutsche Bank Reports Positive Surgery Data From Omeros

Financial news for OMER dated on 2011-03-15: Omeros Reports Q4 Results

Financial news for OMER dated on 2010-10-26: Omeros Upgraded to Strong Buy (OMER)

Financial news for OMER dated on 2009-10-08: Omeris (OMER) IPO Prices At Bottom of Range